

Financial news for ZGNX dated on 2020-06-01: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

Financial news for ZGNX dated on 2020-05-06: Needham Maintains Buy on Zogenix, Lowers Price Target to \$50

Financial news for ZGNX dated on 2020-05-05: Zogenix Q1 EPS \$(0.540) Up From \$(0.830) YoY, Sales \$1.249M May Not Compare To \$380.000K Estimate

Financial news for ZGNX dated on 2020-05-05: The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout

Financial news for ZGNX dated on 2020-05-03: The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace

Financial news for ZGNX dated on 2020-04-23: Shares of several healthcare companies are trading higher. Movement appears market-related as equities gain amid a rebound in oil prices.

Financial news for ZGNX dated on 2020-04-01: Mizuho Maintains Buy on Zogenix, Lowers Price Target to \$64

Financial news for ZGNX dated on 2020-03-19: The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latest Stage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection

Financial news for ZGNX dated on 2020-03-06: Benzinga's Top Upgrades, Downgrades For March 6, 2020

Financial news for ZGNX dated on 2020-03-06: Citigroup Initiates Coverage On Zogenix with Neutral Rating, Announces \$27 Price Target

Financial news for ZGNX dated on 2020-03-04: The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

Financial news for ZGNX dated on 2020-03-04: A Peek Into The Markets: US Stock Futures Jump Ahead Of Economic Data

Financial news for ZGNX dated on 2020-03-04: Zogenix Prices 8.5M Share Public Offering of Common Stock @\$23.50/Share

Financial news for ZGNX dated on 2020-03-03: Zogenix Reports Offering Of Common Stock, No Size Disclosed

Financial news for ZGNX dated on 2020-03-03: The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More

Financial news for ZGNX dated on 2020-03-02: Zogenix Q4 EPS \$(1.26) Misses \$(1.06) Estimate

Financial news for ZGNX dated on 2020-03-02: Earnings Scheduled For March 2, 2020

Financial news for ZGNX dated on 2020-02-29: The Week Ahead In Biotech: COVID-19 Stocks In The Spotlight, Earnings Taper Off

Financial news for ZGNX dated on 2020-02-28: The Daily Biotech Pulse: Sangamo In Genome-Editing Therapy Deal With Biogen, FDA Nod For Biohaven, Passage Bio IPO

Financial news for ZGNX dated on 2020-02-27: Stocks That Hit 52-Week Lows On Thursday

Financial news for ZGNX dated on 2020-02-27: Zogenix Announces FDA Extension Of Review Period For FINTEPLA In Dravet Syndrome

Financial news for ZGNX dated on 2020-02-27: The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy

Financial news for ZGNX dated on 2020-02-26: Stocks That Hit 52-Week Lows On Wednesday

Financial news for ZGNX dated on 2020-02-26: The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates

Financial news for ZGNX dated on 2020-02-25: The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes \$1.6B Opioid Settlement

Financial news for ZGNX dated on 2020-02-13: Zogenix Disclosed Estimated, Unaudited Cash, Cash Equivalents & Marketable Securities As Of Dec 31, 2019 Were \$251.2M

Financial news for ZGNX dated on 2020-02-11: The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology

Financial news for ZGNX dated on 2020-02-10: Zogenix Shares Tick Modestly Lower On Uptick In Volume; Hearing Cautious Comments On Stock Given On CNBC

Financial news for ZGNX dated on 2020-02-10: Stocks That Hit 52-Week Lows On Monday

Financial news for ZGNX dated on 2020-02-10: 95 Biggest Movers From Friday

Financial news for ZGNX dated on 2020-02-07: Mid-Afternoon Market Update: Dow Falls Over 300 Points; Assertio Therapeutics Shares Spike Higher

Financial news for ZGNX dated on 2020-02-07: Mid-Morning Market Update: Markets Open Lower; US Adds 225,000 Jobs For January

Financial news for ZGNX dated on 2020-02-07: Benzinga's Top Upgrades, Downgrades For February 7, 2020

Financial news for ZGNX dated on 2020-02-07: 10 Biggest Price Target Changes For Friday

Financial news for ZGNX dated on 2020-02-07: Zogenix shares are trading lower after Ladenburg Thalmann downgraded the stock from Buy to Neutral and lowered its price target from \$60 to \$35 per share.

Financial news for ZGNX dated on 2020-02-07: Ladenburg Thalmann Downgrades Zogenix to Neutral, Lowers Price Target to \$35

Financial news for ZGNX dated on 2020-02-07: 16 Healthcare Stocks Moving In Friday's Pre-Market Session

Financial news for ZGNX dated on 2020-02-07: 10 Biotechnology Stocks Moving In Friday's Pre-Market Session

Financial news for ZGNX dated on 2020-02-07: The Daily Biotech Pulse: Assertio To Sell Opioid Pain Drug, Milestone Payment For Aduro, Myriad Genetics CEO Resigns

Financial news for ZGNX dated on 2020-02-07: 46 Stocks Moving in Friday's Pre-Market Session

Financial news for ZGNX dated on 2020-02-06: 29 Stocks Moving In Thursday's After-Hours Session

Financial news for ZGNX dated on 2020-02-06: Zogenix shares are trading lower after the company announced a secondary endpoint in its Phase 3 trial of FINTEPLA did not reach statistical significance.

Financial news for ZGNX dated on 2020-02-06: Zogenix Announces Results From Global Pivotal Phase 3 Trial of FINTEPLA For The Treatment Of Lennox-Gastaut Syndrome Met Primary Endpoint; Co. Also Reported FINTEPLA Also Demonstrated Statistically Significant Improvement on Multiple Secondary Endpoints

Financial news for ZGNX dated on 2020-01-17: Stocks That Hit 52-Week Highs On Friday

Financial news for ZGNX dated on 2020-01-17: The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares

Financial news for ZGNX dated on 2019-12-18: The Lancet Publishes Phase 3 Trial Results for Zogenix Investigational Drug FINTEPLA in Dravet Syndrome

Financial news for ZGNX dated on 2019-12-10: Zogenix Option Alert: Feb 21 \$55 Calls at the Ask: 693 @ \$4.75 vs 0 OI; Ref=\$47.105

Financial news for ZGNX dated on 2019-12-06: Resideo, Zogenix And More 'Fast Money Halftime Report' Picks For Dec. 6

Financial news for ZGNX dated on 2019-12-05: Zogenix Reports Will Host Investor Update On FINTEPLA At American Epilepsy Society 2019 Annual Meeting Mon., Dec. 9, 2019

Financial news for ZGNX dated on 2019-12-02: Zogenix Highlights Publication In JAMA Neurology Of Phase 3 Study Of FINTEPLA In Dravet Syndrome Patients Taking Stiripentol-Containing Antiepileptic Drug Regimens

Financial news for ZGNX dated on 2019-12-02: Shares of several healthcare stocks are

trading lower as US equities dip following escalating US-China tensions over Hong Kong. US Stocks further fell on worse-than-expected manufacturing data.

Financial news for ZGNX dated on 2019-11-25: Zogenix Reports FDA Acceptance For Filing Of New Drug Application, Priority Review For FINTEPLA For Treatment Of Dravet Syndrome

Financial news for ZGNX dated on 2019-11-08: Stifel Nicolaus Maintains Buy on Zogenix, Lowers Price Target to \$70

Financial news for ZGNX dated on 2019-11-07: The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs

Financial news for ZGNX dated on 2019-10-25: Zogenix Announces New Data For Its Investigational Drug FINTEPLA In Dravet Syndrome ; Data Showed Clinically Meaningful Convulsive Seizure Reduction In Patients Under 6 Years Old

Financial news for ZGNX dated on 2019-10-21: Needham Initiates Coverage On Zogenix with Buy Rating, Announces \$58 Price Target

Financial news for ZGNX dated on 2019-10-07: Zogenix Presents Positive Clinical Study Results For Investigational Treatment For TK2 Deficiency

Financial news for ZGNX dated on 2019-09-26: The Daily Biotech Pulse: Enanta Aces Midstage NASH Study, Takeda's Ulcerative Colitis Drug Found Superior To AbbVie's, Decision Day For J&J

Financial news for ZGNX dated on 2019-09-26: Zogenix Reports Submission Of New Drug Application For FINTEPLA For Dravet Syndrome

Financial news for ZGNX dated on 2019-09-12: Zogenix Option Alert: Jan 17 \$50 Calls at the Ask: 800 @ \$3.3 vs 4922 OI; Earnings 11/7 After Close [est] Ref=\$42.26

Financial news for ZGNX dated on 2019-09-10: Zogenix Files Prospectus Supplement Relating To Possible Resale Of Other Disposition Of Up To 1.6M Shares

Financial news for ZGNX dated on 2019-08-29: 'Fast Money Halftime Report' Picks For August 29

Financial news for ZGNX dated on 2019-08-27: 50 Biggest Movers From Yesterday

Financial news for ZGNX dated on 2019-08-26: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for ZGNX dated on 2019-08-26: Hearing Stifel Out Defending Zogenix, Unconfirmed

Financial news for ZGNX dated on 2019-08-26: Zogenix shares are trading lower after the company announced it would acquire Modis Therapeutics for \$175 million in cash and \$75 million in Zogenix stock.

Financial news for ZGNX dated on 2019-08-26: Zogenix Will Acquire Modis Therapeutics In \$250M Deal

Financial news for ZGNX dated on 2019-08-26: Zogenix to Acquires Modis Therapeutics for \$250M, \$175M to be Paid in Cash and \$75M in Zogenix Stock

Financial news for ZGNX dated on 2019-08-26: Zogenix Shares Halted, News Pending

Financial news for ZGNX dated on 2019-08-19: Shares of several healthcare companies are trading higher as optimism increased for a resolution to the US-China trade war.

Financial news for ZGNX dated on 2019-08-16: Shares of healthcare companies are trading higher as US markets rebound from recent weakness following a yield curve inversion, which caused recession fears. Trump also recently announced the US would delay China tariffs, renewing hopes of a trade deal.

Financial news for ZGNX dated on 2019-08-06: Zogenix Q2 EPS \$(0.89) Misses \$(0.78) Estimate, Sales \$1.069M Miss \$3.7M Estimate

Financial news for ZGNX dated on 2019-08-06: The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering

Financial news for ZGNX dated on 2019-07-23: Zogenix Enters Supply Agreement With PCI Pharma Services; PCI To Be The Commercial Manufacturer And Supplier Of Co.'s FINTEPLA

Financial news for ZGNX dated on 2019-07-08: Zogenix Completes Enrollment In Phase 3 Trial Of FINTEPLA In Lennox-Gastaut Syndrome

Financial news for ZGNX dated on 2019-06-28: 62 Biggest Movers From Yesterday

Financial news for ZGNX dated on 2019-06-27: Hearing Guggenheim Upgraded Zogenix To Buy; Unconfirmed

Financial news for ZGNX dated on 2019-06-27: 48 Stocks Moving In Thursday's Mid-Day Session

Financial news for ZGNX dated on 2019-06-27: Mid-Morning Market Update: Markets Mostly Higher; Walgreens Earnings Top Views

Financial news for ZGNX dated on 2019-06-27: Zogenix Secures FDA Approval For Resubmission Of Seizure Drug Application

Financial news for ZGNX dated on 2019-06-27: Zogenix shares are trading higher after the company reported an FDA deal to proceed with the resubmission of its FINTEPLA new drug application.

Financial news for ZGNX dated on 2019-06-27: Zogenix Reports FDA Deal To Proceed With Resubmission Of FINTEPLA New Drug Application

Financial news for ZGNX dated on 2019-06-05: Zogenix Option Alert: Jul 19 \$42 Calls at the Ask: 750 @ \$2.3 vs 2349 OI; Ref=\$38.

Financial news for ZGNX dated on 2019-05-08: Zogenix Q1 EPS \$(0.83), Inline

Financial news for ZGNX dated on 2019-04-24: 'Halftime Report' Traders Share Their View On Zogenix, Spotify And Marvell

Financial news for ZGNX dated on 2019-04-14: The Week In Cannabis News: SAFE Banking Act In The Senate, Greenlane's IPO, B-Real, Canopy Growth And More

Financial news for ZGNX dated on 2019-04-10: 46 Biggest Movers From Yesterday

Financial news for ZGNX dated on 2019-04-09: 38 Stocks Moving In Tuesday's Mid-Day Session

Financial news for ZGNX dated on 2019-04-09: SVB Leerink Maintains Outperform on Zogenix, Lowers Price Target to \$48

Financial news for ZGNX dated on 2019-04-09: PiperJaffray Maintains Overweight on Zogenix, Lowers Price Target to \$68

Financial news for ZGNX dated on 2019-04-09: Stifel Nicolaus Maintains Buy on Zogenix, Lowers Price Target to \$61

Financial news for ZGNX dated on 2019-04-09: Mizuho Maintains Buy on Zogenix, Lowers Price Target to \$58

Financial news for ZGNX dated on 2019-04-09: Mid-Morning Market Update: Markets Open Lower; PhaseBio Gets Breakthrough Therapy Designation For PB2452

Financial news for ZGNX dated on 2019-04-09: Benzinga's Top Upgrades, Downgrades For April 9, 2019

Financial news for ZGNX dated on 2019-04-09: FDA Rejects Regulatory Filing For Zogenix Epilepsy Drug; GW Pharma Moves In Sympathy

Financial news for ZGNX dated on 2019-04-09: The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing

Financial news for ZGNX dated on 2019-04-09: 28 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ZGNX dated on 2019-04-09: Zogenix shares are trading lower after the FDA sent a 'refusal to file letter' to the company for its new drug application for FINTEPLA. Guggenheim downgraded the stock from Buy to Neutral.

Financial news for ZGNX dated on 2019-04-09: A Peek Into The Markets: US Stock Futures Edge Lower Ahead Of Job Openings Report

Financial news for ZGNX dated on 2019-04-09: Guggenheim Downgrades Zogenix to Neutral

Financial news for ZGNX dated on 2019-04-08: '\$ZGNX conference call...The FDA's RTF letter arrived on Friday. The company says it was their belief that the non-clinical studies now requested by FDA were not necessary, per prior meetings with the agency.' -Tweet From STAT News' Adam Feuerstein

Financial news for ZGNX dated on 2019-04-08: Zogenix shares trading lower after the company announced it received a refusal to file letter from the FDA related to its FINTEPLA New Drug Application.

Financial news for ZGNX dated on 2019-04-08: Zogenix Shares Resume, Down 27%

Financial news for ZGNX dated on 2019-04-08: GW Pharma Shares Trading Up 3.9% Following Zogenix News Co. Received Refusal To File Letter From FDA Related To Treatment Of Seizures Related To Dravet Syndrome

Financial news for ZGNX dated on 2019-04-08: Zogenix Shares To Resume Trade At 4:30 p.m. EDT

Financial news for ZGNX dated on 2019-04-08: Zogenix Receives Refusal To File Letter From US Food And Drug Administration For FINTEPLA New Drug Application

Financial news for ZGNX dated on 2019-04-08: Zogenix Shares Halted News Pending

Financial news for ZGNX dated on 2019-03-19: Zogenix Enters Exclusive Distribution Agreement With Nippon Shinyaku For FINTEPLA In Japan

Financial news for ZGNX dated on 2019-02-28: Zogenix Q4 EPS \$(0.53) Beats \$(1.04) Estimate

Financial news for ZGNX dated on 2019-02-28: The Daily Biotech Pulse: Bristol-Myers Squibb-Celgene Deal Faces Setback, Syneos Hit By SEC Probe, FDA Cheer For T2 Biosystems

Financial news for ZGNX dated on 2019-02-22: Guggenheim Initiates Coverage On Zogenix with Buy Rating, Announces \$70 Price Target

Financial news for ZGNX dated on 2019-02-06: PiperJaffray On Zogenix Expects 'Safety Concerns to be Put to Rest & FDA Approval of Fintepla by Dec 19'; Reiterates Overweight

Financial news for ZGNX dated on 2019-02-06: Zogenix Reports Submission Of New Drug Application, Marketing Authorization Application To FDA, EMA, Respectively, For FINTEPLA Dravet Syndrome Treatment

Financial news for ZGNX dated on 2018-12-03: Zogenix Reports Phase 3 Trial Results On Efficacy, Safety Of FINTEPLA In Dravet Syndrome: Data from Second Pivotal Phase 3 Trial Consistent with Results of First Phase 3 Trial in Showing Highly Significant Convulsive Seizure Reduction for FINTEPLA

Financial news for ZGNX dated on 2018-12-02: The Week Ahead In Biotech: ASH Presentations Pick Up Pace, PDUFA Dates, Clinical Trials And IPOs

Financial news for ZGNX dated on 2018-12-02: Zogenix Presents Positive Findings on the Impact of Treatment with FINTEPLA on Everyday Executive Function in Patients with Dravet Syndrome at AES 2018

Financial news for ZGNX dated on 2018-11-13: Leerink Swann Initiates Coverage On Zogenix with Outperform Rating, Announces \$60 Price Target

Financial news for ZGNX dated on 2018-11-08: Zogenix Q2 EPS \$(0.82) Up From \$(0.90) YoY

Financial news for ZGNX dated on 2018-09-14: Zogenix Has \$3.4B Opportunity With Pediatric Epilepsy Asset, BofA Says In Bullish Initiation

Financial news for ZGNX dated on 2018-09-14: Benzinga's Top Upgrades, Downgrades For September 14, 2018

Financial news for ZGNX dated on 2018-09-14: Bank of America Initiates Coverage On Zogenix with Buy Rating, Announces \$63 Price Target

Financial news for ZGNX dated on 2018-09-12: Northland Securities Initiates Coverage On Zogenix with Outperform Rating, Announces \$70 Price Target

Financial news for ZGNX dated on 2018-09-07: Benzinga's Top Upgrades, Downgrades For September 7, 2018

Financial news for ZGNX dated on 2018-09-07: A Peek Into The Markets: US Stock Futures Down; All Eyes On Jobs Report

Financial news for ZGNX dated on 2018-09-07: B. Riley FBR Initiates Coverage On Zogenix with Buy Rating, Announces \$116 Price Target

Financial news for ZGNX dated on 2018-09-04: Zogenix Announces Publication Of Phase 2

Study Results Showing ZX008 Provides Durable Reduction In Seizure Frequency In Patients With Lennox-Gastaut Syndrome

Financial news for ZGNX dated on 2018-08-30: Zogenix Highlights Data From 2 Presentations From Sibling Voices Survey

Financial news for ZGNX dated on 2018-08-07: Zogenix Prices 6M Share Common Stock Offering At \$52/Share

Financial news for ZGNX dated on 2018-08-07: The Daily Biotech Pulse: FDA Snub For Gemphire, Ligand Earnings, Insmed's Antibiotic Faces FDA Panel

Financial news for ZGNX dated on 2018-08-06: Zogenix Announces 6M Share Common Stock Offering

Financial news for ZGNX dated on 2018-08-06: Zogenix Q2 EPS \$(0.83) Up From \$(0.90) YoY

Financial news for ZGNX dated on 2018-07-16: 38 Biggest Movers From Friday

Financial news for ZGNX dated on 2018-07-13: Pot Stocks, ETFs, Top News And Data From The Cannabis Industry This Week

Financial news for ZGNX dated on 2018-07-13: Benzinga's Daily Biotech Pulse: Amgen Resubmits Osteoporosis Drug BLA, Auris Medical Prices Offering

Financial news for ZGNX dated on 2018-07-13: 44 Biggest Movers From Yesterday

Financial news for ZGNX dated on 2018-07-12: Mid-Afternoon Market Update: Dow Up Over 200 Points; Zogenix Shares Gain On Positive Phase 3 Data In Dravet Syndrome Study

Financial news for ZGNX dated on 2018-07-12: 30 Stocks Moving In Thursday's Mid-Day Session

Financial news for ZGNX dated on 2018-07-12: Mid-Day Market Update: Crude Oil Down Over 1%; IZEA Shares Spike Higher

Financial news for ZGNX dated on 2018-07-12: Mid-Morning Market Update: Markets Open Higher; Delta Air Lines Earnings Beat Estimates

Financial news for ZGNX dated on 2018-07-12: Mizuho Raises Zogenix Price Target From \$51 To \$69

Financial news for ZGNX dated on 2018-07-12: Zogenix Soars On Positive Phase 3 Data In Dravet Syndrome Study

Financial news for ZGNX dated on 2018-07-12: Zogenix Shares Up 19.4% Premarket After Co. Announced Second Trial Success Of ZX008; Drug Reduced Monthly Convulsive Seizures By Over 50% vs Placebo In Children And Teenagers With Dravet's Syndrome, A Rare And Severe Type Of Epilepsy

Financial news for ZGNX dated on 2018-07-12: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for ZGNX dated on 2018-07-12: UPDATE: Zogenix Says US, EU Regulatory Submission On Track For Q4'18

Financial news for ZGNX dated on 2018-07-12: UPDATE: Zogenix Says ZX008 Demonstrated Statistical Significance In All Key Secondary Endpoints

Financial news for ZGNX dated on 2018-07-12: Zogenix Reports Top-Line Results From Second Pivotal Phase 3 Trial Of ZX008 In Dravet Syndrome: Met Primary Endpoint

Financial news for ZGNX dated on 2018-07-10: Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

Financial news for ZGNX dated on 2018-07-03: Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium

Financial news for ZGNX dated on 2018-06-30: The Week Ahead In Biotech: Delayed Clinical Trial Releases In Focus

Financial news for ZGNX dated on 2018-05-09: Zogenix Q1 EPS \$(0.87) Beats \$(0.90) Estimate

Financial news for ZGNX dated on 2018-04-27: Zogenix Claims ZX008 Patients Experienced Significant Improvements on Select Measures of Quality of Life and Executive Function Compared to Those on Placebo

Financial news for ZGNX dated on 2018-04-25: Zogenix Reports Patients on ZX008 Achieved Significant, Clinically Meaningful Reduction in Total Seizure Frequency Compared to Those on Placebo

Financial news for ZGNX dated on 2018-03-06: Zogenix Reports Q4 EPS \$(1.17) vs \$(0.90) Est.

Financial news for ZGNX dated on 2018-02-23: Why Leerink Adjusted Upside Expectations For 3 Biotechs

Financial news for ZGNX dated on 2018-02-23: Leerink Swann Maintains Outperform on Zogenix, Raises price target to \$54.00

Financial news for ZGNX dated on 2018-02-06: Zogenix Reports Receipt Of FDA Breakthrough Designation For ZX008 In Dravet Syndrome

Financial news for ZGNX dated on 2018-01-31: Zogenix Reports Closing Enrollment In Second ZX008 Phase 3 Trial In Dravet Syndrome

Financial news for ZGNX dated on 2017-12-22: Zogenix 8-K Shows Co. \$75M Offering Via Selling Holders

Financial news for ZGNX dated on 2017-12-05: 32 Biggest Movers From Yesterday

Financial news for ZGNX dated on 2017-12-04: Mid-Afternoon Market Update: Dow Gains Over 200 Points; Astrotech Shares Spike Higher

Financial news for ZGNX dated on 2017-12-04: 30 Stocks Moving In Monday's Mid-Day Session

Financial news for ZGNX dated on 2017-12-04: Mid-Day Market Update: General Cable Rises Following Acquisition News; Ra Pharmaceuticals Shares Plunge

Financial news for ZGNX dated on 2017-12-04: Mid-Morning Market Update: Markets Open Higher; CVS To Buy Aetna For \$69B

Financial news for ZGNX dated on 2017-12-04: Zogenix Announces New 'Positive' Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Financial news for ZGNX dated on 2017-11-27: As Zogenix Develops Its Seizure Treatment Pipeline, Analyst Predicts More Upside

Financial news for ZGNX dated on 2017-11-27: Benzinga's Top Upgrades, Downgrades For November 27, 2017

Financial news for ZGNX dated on 2017-11-27: JMP Securities Initiates Coverage On Zogenix with Market Outperform Rating, Announces \$56.00 Price Target

Financial news for ZGNX dated on 2017-11-14: 13F Filing From Baker Bros Shows New Stake In GW Pharmaceuticals, Slight Increase To Ignyta Stake, Exited Stake In Palatin Technologies and Zogenix

Financial news for ZGNX dated on 2017-11-07: Zogenix Reports Q3 EPS \$(1.68) vs \$(0.93) Est.

Financial news for ZGNX dated on 2017-10-31: Zogenix To Report Q3 Earnings On Tues., Nov. 7 After Market Close

Financial news for ZGNX dated on 2017-10-26: 22 Stocks To Watch After President Trump Declares Opioid Epidemic A National Health Emergency

Financial news for ZGNX dated on 2017-10-26: Watch Non-Opioid Pain/Rare Disease Treatment Names Amid Comments From First Lady Trump Related To America's Opioid Crisis

Financial news for ZGNX dated on 2017-10-13: Benzinga's Option Alert Recap From October 13

Financial news for ZGNX dated on 2017-10-13: Zogenix Option Alert: Nov 17 \$39 Puts Sweep (37) at the Bid: 1156 @ \$2.801 vs 24 OI; Ref=\$39.65

Financial news for ZGNX dated on 2017-10-10: 25 Stocks Moving In Tuesday's Pre-Market Session

Financial news for ZGNX dated on 2017-10-03: Zogenix, 10%+ Owner Edelman Buys 300,000 @ Avg Price: \$37.50 -Form4

Financial news for ZGNX dated on 2017-10-02: Zogenix Prices 6.7M Share Offering @ \$37.50/Share

Financial news for ZGNX dated on 2017-10-02: What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?

Financial news for ZGNX dated on 2017-10-02: Zogenix Reports 4.3M Share Common Stock Offering

Financial news for ZGNX dated on 2017-10-02: 5 Stocks To Watch For October 2, 2017

Financial news for ZGNX dated on 2017-09-29: Mid-Afternoon Market Update: Envirostar Drops After Fiscal 2017 Results; Zogenix Shares Spike Higher

Financial news for ZGNX dated on 2017-09-29: Mid-Day Market Update: A10 Networks Gains On Strong Guidance; Louisiana-Pacific Shares Slide

Financial news for ZGNX dated on 2017-09-29: Stifel Raises Price Target On Zogenix From \$26 To \$55 In Mid-Day Note

Financial news for ZGNX dated on 2017-09-29: 18 Biggest Mid-Day Gainers For Friday

Financial news for ZGNX dated on 2017-09-29: Mid-Morning Market Update: Markets Mixed; KB Home Profit Beats Estimates

Financial news for ZGNX dated on 2017-09-29: Zogenix Offers Slides For Study 1 Phase 3 Top-Line Results Related To Dravet Syndrome Treatment

Financial news for ZGNX dated on 2017-09-29: A Peek Into The Markets: U.S. Stock Futures Mixed Ahead Of Key Economic Reports

Financial news for ZGNX dated on 2017-09-29: Zogenix's Dravet Syndrome Treatment Returns 'Strong' Results

Financial news for ZGNX dated on 2017-09-29: Zogenix Shares Resume Trade, Now Up 183%

Financial news for ZGNX dated on 2017-09-29: Zogenix Shares To Resume Trade At 7:30 a.m. EDT

Financial news for ZGNX dated on 2017-09-29: Adam Feuerstein Tweets: Those \$ZGNX study results look strong. 64% average reduction in monthly seizure rate vs. placebo.

Financial news for ZGNX dated on 2017-09-29: Zogenix Reports Top-Line Results From Pivotal Phase 3 Trial Of ZX008 In Dravet Syndrome: 'Primary Endpoint Achieved'

Financial news for ZGNX dated on 2017-09-29: UPDATE: Zogenix Says 'ZX008 Also Demonstrated Statistical Significance in All Key Secondary Endpoints'

Financial news for ZGNX dated on 2017-09-29: Zogenix Shares Halted News Pending

Financial news for ZGNX dated on 2017-09-28: Downside In Zogenix Shares Intensifies As \$13 Support Level Breaks; Stock Down 8.9% For Session

Financial news for ZGNX dated on 2017-09-07: Mizuho Initiates Coverage On Zogenix with Buy Rating, Announces \$28.00 Price Target

Financial news for ZGNX dated on 2017-08-08: Zogenix Reports Q2 EPS \$(0.93) vs \$(0.89) Est., Sales \$7.1M vs \$3.48M Est.

Financial news for ZGNX dated on 2017-08-03: Zogenix Says on August 1, 2017 Terminated License Agreement Dated July 11, 2011 with Durrect Regarding Relday

Financial news for ZGNX dated on 2017-06-22: 8-K From Zogenix Shows Previously-Announced FDA Granted ZX008 Orphan Drug Designation For Treatment Of LGS

Financial news for ZGNX dated on 2017-06-09: Watch These 8 Huge Call Purchases In Friday Trade

Financial news for ZGNX dated on 2017-06-08: Benzinga's Option Alert Recap From June 8

Financial news for ZGNX dated on 2017-06-08: Option Alert: Zogenix Jul 20.0 Calls: 3000 @ ASK \$0.15: 3000 traded vs 6180 OI: Earnings 8/9 After Close (est) \$14.50 Ref

Financial news for ZGNX dated on 2017-05-04: Zogenix Reports Q1 EPS \$(0.86) vs \$(0.88) Est., Sales \$2.7M vs \$4.23M Est.

Financial news for ZGNX dated on 2017-04-27: Zogenix Completes Enrollment In ZX008

Phase 3 Trial

Financial news for ZGNX dated on 2017-04-05: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for ZGNX dated on 2017-03-13: Mid-Day Market Update: AMEC Foster Wheeler Surges Following Wood Group Bid; Aralez Pharmaceuticals Shares Plunge

Financial news for ZGNX dated on 2017-03-10: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for ZGNX dated on 2017-03-09: Zogenix Reports Q4 EPS \$(0.95) vs \$(0.84) Est., Sales \$11M vs \$5.24M Est.

Financial news for ZGNX dated on 2017-03-01: Zogenix Receives Orphan Drug Designation in the European Union for ZX008

Financial news for ZGNX dated on 2017-03-01: Zogenix Announces EC Designated ZX008 as Orphan Medicinal Product

Financial news for ZGNX dated on 2017-02-22: Zogenix Shares Up 4.76% In Late-Day Trading; Earlier 13G Filing Showed Perceptive Advisors Reporting 5.46% Stake In Co.

Financial news for ZGNX dated on 2017-02-13: UPDATE: Zogenix Says Safety, Efficacy Portion of 1504, ZX008 Study Expanded from EU to Include Sites in U.S. and Canada

Financial news for ZGNX dated on 2017-02-13: Zogenix Reports Initiation of Clinical Efficacy Portion of Study 1504, ZX008 in Dravet Syndrome

Financial news for ZGNX dated on 2017-01-30: Zogenix Reports Issuance of U.S. Patent for ZX008 in Dravet Syndrome

Financial news for ZGNX dated on 2017-01-05: Zogenix Announces CFO Transition, Ann Rhoads TO LEave Company, Names Michael Smith CFO

Financial news for ZGNX dated on 2016-12-05: Zogenix Reports New Efficacy and Safety Data for ZX008 in Treatment of Seizures in Lennox Gastaut Syndrome & Dravet Syndrome

Financial news for ZGNX dated on 2016-11-29: Oppenheimer Life Sciences Summit Takes Place Today; Presenters Include Zogenix, Eisai Biopharmaceuticals, And Cellectis

Financial news for ZGNX dated on 2016-11-11: Aegis Capital Initiates Coverage On Zogenix, Inc. - Common Stock at Buy, Announces \$28.00

Financial news for ZGNX dated on 2016-11-11: Hearing Aegis Out Positive On Zogenix

Financial news for ZGNX dated on 2016-11-07: Zogenix Reports Q3 Loss/Share \$0.69 vs \$0.96 Est Loss/Share, Revenue \$6.6M vs \$3.1M Est

Financial news for ZGNX dated on 2016-11-07: Zogenix Reports Q3 EPS \$(0.69) vs \$(0.96) Est., Sales \$6.6M vs \$3.1M Est.

Financial news for ZGNX dated on 2016-10-04: Leerink Rates Zogenix Outperform Ahead Of AES Meeting

Financial news for ZGNX dated on 2016-10-04: Leerink Swann Assumes Zogenix at Outperform, Announces \$17.00 PT

Financial news for ZGNX dated on 2016-08-10: Mid-Morning Market Update: Markets Mostly Lower; Michael Kors Issues Downbeat Guidance

Financial news for ZGNX dated on 2016-08-09: Zogenix Reports Q2 EPS \$(0.76) vs. Est. \$(0.95), Rev. \$2.088M vs. Est. \$1.3M

Financial news for ZGNX dated on 2016-06-22: Stocks Hitting 52-Week Lows

Financial news for ZGNX dated on 2016-06-21: Zogenix Reports Deal to Refinance Debt, Interest-Only Repayment Provision Results in \$10M Increase to Co.'s Expected Cash Balance at End of '17

Financial news for ZGNX dated on 2016-06-07: Zogenix Reports Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome

Financial news for ZGNX dated on 2016-05-10: Zogenix Reports Q1 EPS \$(0.42) vs. Est. \$(0.62), Rev. \$9.2M vs. Est. \$4.9M

Financial news for ZGNX dated on 2016-05-10: Zogenix Reports EPS \$(0.42) vs \$(0.62) Est., Sales \$9.2M vs \$4.9M Est.

Financial news for ZGNX dated on 2016-05-05: Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome

Financial news for ZGNX dated on 2016-03-17: Mid-Morning Market Update: Markets Mostly Lower; Michaels Tops Q4 Expectations

Financial news for ZGNX dated on 2016-03-15: Brean Capital Positive On Zogenix, Says Favorable Phase 3 Of Cannabidiol Is Positive For ZX008, Sees Potential For Study 504 Read-Out To Yield Support For Premium Pricing & Exclusivity In EU, Maintains Buy And \$28 PT

Financial news for ZGNX dated on 2016-03-10: Zogenix Reports Q4 EPS \$(0.36) vs \$(0.69) Est., Sales \$6.1M vs \$6.4M Est.

Financial news for ZGNX dated on 2016-01-19: Zogenix Reports Fast Track Designation from FDA for Development of ZX008 in Dravet Syndrome

Financial news for ZGNX dated on 2016-01-11: Zogenix Reports Start of Phase 3 Program for ZX008 in Dravet Syndrome

Financial news for ZGNX dated on 2015-12-14: Zogenix Reports FDA Acceptance of IND App for ZX008 Phase 3 Trial in Dravet Syndrome

Financial news for ZGNX dated on 2015-12-07: 8-K from Zogenix Shows New Data Demonstrating Sustained Effectiveness, CV-Related Safety for Patients Treated with ZX008

Financial news for ZGNX dated on 2015-12-07: Zogenix Reports New Efficacy, Safety Data on ZX008 for Seizure Treatment in Dravet Syndrome

Financial news for ZGNX dated on 2015-11-25: Mid-Day Market Update: HP Slides Following Q4 Results; Deere Shares Surge

Financial news for ZGNX dated on 2015-11-25: Zogenix to Offer New Data on ZX008 for Dravet Syndrome at AAES Meeting

Financial news for ZGNX dated on 2015-11-09: Zogenix Reports Q3 EPS \$(0.65) vs \$(0.74) Est., Sales \$9.1M vs \$5.9M Est.

Financial news for ZGNX dated on 2015-10-19: Monday's After-Hours Movers: IBM, Sonic, Flextronics And More

Financial news for ZGNX dated on 2015-10-19: UPDATE: Zogenix Says ZX008 Expected to Enter Phase 3 Trials in Q4'15

Financial news for ZGNX dated on 2015-10-19: Zogenix Issues Regulatory Update for ZX008

Financial news for ZGNX dated on 2015-10-08: RA Capital Management Reports 7.5% Passive Stake in Zogenix

Financial news for ZGNX dated on 2015-10-06: Leerink Chats With Biotech Management, Names 20 Stocks To Buy Now

Financial news for ZGNX dated on 2015-10-05: Shares of Zogenix Spike Nearly 2% Over Last Few Mins, Now In Positive Territory

Financial news for ZGNX dated on 2015-09-30: Zogenix Reports Positive Top-Line Results From Relday(TM) Phase 1b Multi-Dose Clinical Trial

Financial news for ZGNX dated on 2015-08-11: 4 More Biotechs Leerink Is Looking At Post-Earnings

Financial news for ZGNX dated on 2015-08-10: Zogenix Reports Q2 EPS \$3.78 may Not Compare, Sales \$7.4M vs Est \$5.13M

Financial news for ZGNX dated on 2015-07-28: Zogenix Reports 3.8M Share Offering of Common Stock

Financial news for ZGNX dated on 2015-07-21: New Alzheimer's Trials Could Produce The Most Important Drugs In History

Financial news for ZGNX dated on 2015-07-15: Mid-Day Market Update: Receptos Jumps After Merger News; Marten Transport Shares Slide

Financial news for ZGNX dated on 2015-07-14: Mid-Afternoon Market Update: Micron Gains On Rumor Of Tsinghua Bid; Navient Shares Drop

Financial news for ZGNX dated on 2015-07-14: UPDATE: Zogenix Sees Co. Submitting IND

Application to Begin Phase 3 Trials for ZX008 to FDA During Aug.

Financial news for ZGNX dated on 2015-07-14: 8-K from Zogenix Shows Co. Seeking to Enroll 105 Patients in Each of the Two Planned Double-Blind, Randomized, Controlled Phase 3 Trials for ZX008

Financial news for ZGNX dated on 2015-07-02: Mid-Morning Market Update: Markets Edge Higher; Centene To Acquire Health Net For \$6.3B

Financial news for ZGNX dated on 2015-06-24: Cantor Analyst: Durect Is Worth \$3/Share, So Buy It

Financial news for ZGNX dated on 2015-06-18: Zogenix Board Approves 1-for-8 Reverse Split

Financial news for ZGNX dated on 2015-05-27: Zogenix Announces New Efficacy Data from Long-Term Study of Low-Dose Fenfluramine for Treatment of Dravet Syndrome

Financial news for ZGNX dated on 2015-05-22: Option Alert: Zogenix Jan 2017 \$2.5 Call; 1000 Contract Trade at Ask @\$0.40

Financial news for ZGNX dated on 2015-05-22: Option Alert: Zogenix Jan 2017 \$2.5 Call; 1000 Contract Trade at Ask @\$0.40; Now \$1.40

Financial news for ZGNX dated on 2015-05-19: Option Alert: Zogenix Jan 2017 \$2.5 Call; 1000 Contract Trade at Ask @\$0.40; Now \$1.40

Financial news for ZGNX dated on 2015-05-11: Zogenix Reports Q1 Loss \$0.15 Vs Est Loss \$0.13, Sales \$4.61M Vs Est \$8.54M

Financial news for ZGNX dated on 2015-04-27: Zogenix Names Stephen Farr as CEO, Will Continue as Pres

Financial news for ZGNX dated on 2015-04-13: Empire Asset Management Initiates Coverage on Zogenix at Buy, Announces \$5.00 PT

Financial news for ZGNX dated on 2015-03-26: Zogenix Announces First Patient Dosed in Relday Multi-Dose Clinical Study

Financial news for ZGNX dated on 2015-03-11: Morning Market Losers

Financial news for ZGNX dated on 2015-03-11: Benzinga's Top #PreMarket Losers

Financial news for ZGNX dated on 2015-03-11: William Blair Downgrades Zogenix to Market Perform

Financial news for ZGNX dated on 2015-03-10: UPDATE: Zogenix Posts Q4 Loss

Financial news for ZGNX dated on 2015-03-10: PREVIEW: Pernix, Zogenix to Resume Trading at 4:35 PM ET

Financial news for ZGNX dated on 2015-03-10: UPDATE: Pernix Will Make Upfront Payment Which Includes ~\$30M in Cash, \$20M in Shares, Zogenix Will Be Eligible for Milestone Payments Up to \$283.5M

Financial news for ZGNX dated on 2015-03-10: Zogenix Reports Q4 Loss of \$0.14/Share vs Loss of \$0.11/Share Est., Sales \$14.9M vs \$12.74M Est.

Financial news for ZGNX dated on 2015-03-10: Pernix Announces Will Acquire Zohydro ER Franchise from Zogenix for ~\$100M

Financial news for ZGNX dated on 2015-03-10: Zogenix Shares Halted News Pending

Financial news for ZGNX dated on 2015-02-02: Zogenix Received FDA Approval, Now What?

Financial news for ZGNX dated on 2015-02-01: Zogenix Receives FDA Approval Of New Formulation Of Zohydro ER

Financial news for ZGNX dated on 2015-01-27: Option Alert: Zogenix Feb \$2 Call; 1291 Contract Trade at Ask @\$0.10; Now \$1.43

Financial news for ZGNX dated on 2015-01-26: What Investors Are Watching Ahead of Zogenix's FDA Approval Decision

Financial news for ZGNX dated on 2015-01-12: Zogenix Announces 2014 Guidance, Expects To Have Ended Year With \$42.4M Cash

Financial news for ZGNX dated on 2015-01-07: What Investors Should Expect From Rockwell Medical's Next FDA Decision

Financial news for ZGNX dated on 2014-12-30: Zogenix Spikes to High

Financial news for ZGNX dated on 2014-12-29: Brean Capital Initiates Coverage On Zogenix

Financial news for ZGNX dated on 2014-12-29: Brean Capital Initiates Coverage on Zogenix at Buy, Announces \$2.50 PT

Financial news for ZGNX dated on 2014-12-01: Zogenix Reports Publication of Long-Term Phase 3 Open-Label Study of Safety, Tolerability, Effectiveness of Zohydro(R) ER

Financial news for ZGNX dated on 2014-11-20: Purdue Pharma Wins Approval Of An Extended-Release Pure Hydrocodone Painkiller

Financial news for ZGNX dated on 2014-11-17: Events for the Week of Nov. 17-21, 2014

Financial news for ZGNX dated on 2014-10-31: Zogenix and Purdue Pharma Exchange Waivers of Regulatory Exclusivity for Extended-Release Hydrocodone Products

Financial news for ZGNX dated on 2014-10-27: Zogenix Announces Purchase of Brabant Pharma for \$20M in Cash, \$15M in Shares

Financial news for ZGNX dated on 2014-10-01: UPDATE: Zogenix Submits Modified Formulation of Zohydro ER with Potential Abuse Deterrent Properties for FDA Review

Financial news for ZGNX dated on 2014-10-01: Zogenix Submits Modified Formulation of Zohydro ER with Potential Abuse Deterrent Properties for FDA Review

Financial news for ZGNX dated on 2014-09-18: 8-K from Zogenix Shows Co. Entered Into Third Agreement to License Deal with Daravita: Has Been Granted Exclusive License in US, to Certain IP Rights Related to Hydrocodone Bitartrate

Financial news for ZGNX dated on 2014-09-18: New Data From Open Label Study Shows Zohydro ER Reduced Pain and Improved Function in People With Chronic Pain

Financial news for ZGNX dated on 2014-09-02: Zogenix Reports Zohydro ER Shows Sustained 12-Hour Pain Relief

Financial news for ZGNX dated on 2014-08-05: Zogenix, Inc. Reports Q2 EPS of \$(0.19) vs \$(0.16) Est

Financial news for ZGNX dated on 2014-08-05: Zohydro Gains Massachusetts Approval, Acts As Minor Catalyst For Zogenix

Financial news for ZGNX dated on 2014-08-01: Zogenix Announces Departure of Chief Commercial Officer, Scott Shively

Financial news for ZGNX dated on 2014-08-01: Zogenix Spikes Lower

Financial news for ZGNX dated on 2014-07-17: Zogenix Announces David Brushwood, J.D., R.Ph., Joins External Safe Use Board

Financial news for ZGNX dated on 2014-07-09: Zogenix Announces Positive Development on US District Court Ruling, Says MA District Court Upholding Prior Decision

Financial news for ZGNX dated on 2014-07-08: Massachusetts Must Face Lawsuit Brought By Zogenix Over Painkiller Ban - Bloomberg

Financial news for ZGNX dated on 2014-07-02: Morning Market Movers

Financial news for ZGNX dated on 2014-07-02: Zogenix Provides Update On Development Of Abuse Deterrent Formulations Of Zohydro ER

Financial news for ZGNX dated on 2014-06-06: RF Lafferty & Co. Initiates Coverage on Zogenix, Inc. at Buy, Announces \$3.50 PT

Financial news for ZGNX dated on 2014-05-19: Zogenix Announces Closing of Sale of SUMAVEL DosePro Migraine Therapy to Endo Int'l, Zogenix Repaid \$40M in Debt to Healthcare Royalty Partners

Financial news for ZGNX dated on 2014-05-09: Benzinga's Top #PreMarket Losers

Financial news for ZGNX dated on 2014-05-08: Zogenix, Inc. Reports Q1 EPS of \$(0.20) vs \$(0.17) Est; Revenue of \$7.67M vs \$8.71M Est

Financial news for ZGNX dated on 2014-05-02: Zogenix Reports Inducement Awards Granted

Financial news for ZGNX dated on 2014-04-25: Stifel Nicolaus Maintains Buy on Zogenix, Inc., Lowers PT to \$5.00

Financial news for ZGNX dated on 2014-04-24: Morning Market Movers

Financial news for ZGNX dated on 2014-04-24: Benzinga's Top #PreMarket Gainers

Financial news for ZGNX dated on 2014-04-24: Zogenix Shares to Resume Trade at 8AM EDT

Financial news for ZGNX dated on 2014-04-24: Zogenix Announces Sale of SUMAVEL DosePro Migraine Therapy to Endo International for \$85M, Up to \$20M Milestone Payments

Financial news for ZGNX dated on 2014-04-24: Zogenix Halted News Pending

Financial news for ZGNX dated on 2014-04-23: Zogenix Responds to Governor's Action Singling Out Zohydro ER in Massachusetts

Financial news for ZGNX dated on 2014-04-16: Morning Market Movers

Financial news for ZGNX dated on 2014-04-16: Benzinga's Top #PreMarket Gainers

Financial news for ZGNX dated on 2014-04-16: UPDATE: Zogenix-Says Court Granted Temporary Restraining Order Preventing Implementation of Massachusetts Ban of Zohydro ER Extended-Release Capsules =8-K

Financial news for ZGNX dated on 2014-04-15: UPDATE: Zogenix Announces Ruling Preventing Implementation of MA. Gov.'s Order Which Prevented Access to Zohydro ER

Financial news for ZGNX dated on 2014-04-15: Zogenix Announces Ruling Preventing Implementation of MA. Gov.'s Order Which Prevented Access to Zohydro ER

Financial news for ZGNX dated on 2014-04-15: Zogenix Shares Volatile Following Boston Globe Story 'Mass. can't block sale of painkiller, judge rules'

Financial news for ZGNX dated on 2014-04-15: Zogenix Files 3-Count Complaint Alleging Massachusetts's Emergency Banning of Zohydro ER is Unconstitutional; US District Court Allows Zogenix Preliminary Injunction Suspending Enforcement of Ban

Financial news for ZGNX dated on 2014-04-09: Morning Market Movers

Financial news for ZGNX dated on 2014-04-09: Benzinga's Top #PreMarket Gainers

Financial news for ZGNX dated on 2014-04-09: Zogenix Requests Court Order Staying FDA Ban on Zohydro

Financial news for ZGNX dated on 2014-04-07: Zogenix Announces Legal Action in Federal Court Taken, Looking for Injunction on Massachusetts Ban of Zohydro ER

Financial news for ZGNX dated on 2014-04-02: Zogenix Says DEA Administrator Stating Misinformation Regarding Zohydro ER

Financial news for ZGNX dated on 2014-03-28: Zogenix Says Massachusetts Denies Patients a Legitimate Option for Severe Chronic Pain

Financial news for ZGNX dated on 2014-03-26: Zogenix Appoints James Breitmeyer to Its Board of Directors

Financial news for ZGNX dated on 2014-03-21: Zogenix CEO Says Reports Have Been Including False and Misleading Statements About Company, Product

Financial news for ZGNX dated on 2014-03-14: Morning Losers for Friday, March 14, 2014

Financial news for ZGNX dated on 2014-03-14: Benzinga's Top #PreMarket Losers

Financial news for ZGNX dated on 2014-03-13: FDA's Hamburg Defends Approval of Zogenix Zohydro, Says It Is Very Important, 'Unique' Opioid to Treat Pain

Financial news for ZGNX dated on 2014-03-12: Morning Movers for March 12th, 2014

Financial news for ZGNX dated on 2014-03-12: Morning Market Losers

Financial news for ZGNX dated on 2014-03-12: Benzinga's Top #PreMarket Losers

Financial news for ZGNX dated on 2014-03-11: Mid-Afternoon Market Update: Fuel Cell Companies Reverse Sharply on Citron Research Report

Financial news for ZGNX dated on 2014-03-05: Zogenix Reports Q4 Earnings; Shares Soar 5%

Financial news for ZGNX dated on 2014-03-05: After-Hours Movers Mar. 5, 2014: ERII, PXLW, BIOD, SEED Higher, DVAX, LYV Lower

Financial news for ZGNX dated on 2014-03-05: Zogenix, Inc. Reports Q4 EPS of \$(0.28) vs \$(0.09) Est; Revenue of \$9.92M vs \$8.68M Est

Financial news for ZGNX dated on 2014-03-05: Earnings Scheduled For March 5, 2014

Financial news for ZGNX dated on 2014-03-03: Morning Losers for Mar. 3, 2014: YNDX, CETV, AKRX, CPST, LIVE

Financial news for ZGNX dated on 2014-02-27: Mornings Movers for Feb. 27, 2014: PEIX, JCP, SYMX, CIE, SHLD, BBY Higher, INO, NDLS, HK, CY, DYAX Lower

Financial news for ZGNX dated on 2014-02-24: Human Shows Coverage for Zohydro ER

Financial news for ZGNX dated on 2014-02-13: UPDATE: Zogenix 801 Efficacy Study Met Primary Endpoint

Financial news for ZGNX dated on 2014-02-13: Zogenix Says Study from Zohydro Met Primary Endpoint

Financial news for ZGNX dated on 2014-02-12: Zogenix Announces Establishment of External Safe-Use Board for Zohydro ER

Financial news for ZGNX dated on 2014-02-11: Zogenix Offers Update on Zohydro ER, Says Ready for Shipment to Wholesalers, Expecting Commercial Start Early March

Financial news for ZGNX dated on 2014-02-03: Option Alert; Zogenix Jul \$5 Call; 2,500 Contract Trade Between Bid and Ask @\$0.70; Currently \$4.16

Financial news for ZGNX dated on 2014-02-03: Benzinga's Top #PreMarket Losers

Financial news for ZGNX dated on 2014-01-13: Zogenix Sees Q4 Gross Product Sales ~\$14M, Sees Gross Margin Harmed by \$1.3M Charge

Financial news for ZGNX dated on 2013-12-20: Zogenix Announces Granting of Inducement Award Under NASDAQ Listing Rule 5635(c)(4)

Financial news for ZGNX dated on 2013-12-17: Zogenix Names Bradley Galer Chief Medical Officer

Financial news for ZGNX dated on 2013-12-17: Benzinga's Top #PreMarket Gainers

Financial news for ZGNX dated on 2013-12-11: Zogenix Announces Granting of Inducement Wins for Options on 571K Shares, Have Ten-Year Term-Exercise Price ~\$3.12/Share

Financial news for ZGNX dated on 2013-12-10: Zogenix Announces FDA Approval of 4mg SUMAVEL DosePro Needle-Free Delivery System

Financial news for ZGNX dated on 2013-11-14: Benzinga's Top Upgrades

Financial news for ZGNX dated on 2013-11-14: Benzinga's Top #PreMarket Gainers

Financial news for ZGNX dated on 2013-11-14: UPDATE: Oppenheimer Upgrades Zogenix Following Zohydro Approval

Financial news for ZGNX dated on 2013-11-14: Oppenheimer Upgrades Zogenix, Inc. to Outperform, Announces \$5.00 PT

Financial news for ZGNX dated on 2013-11-05: Zogenix Prices 26.66M Share Offering at \$2.25/Share

Financial news for ZGNX dated on 2013-11-04: Benzinga's Top #PreMarket Losers

Financial news for ZGNX dated on 2013-11-04: US Stock Futures Up Ahead Of Factory Orders Data

Financial news for ZGNX dated on 2013-11-04: Zogenix Announces \$60M Common Stock Offering

Financial news for ZGNX dated on 2013-10-29: UPDATE: Stifel Upgrades Zogenix Following Approval of Zohydro

Financial news for ZGNX dated on 2013-10-29: Stifel Nicolaus Upgrades Zogenix, Inc. to Buy, Announces \$5.00 PT

Financial news for ZGNX dated on 2013-10-28: William Blair Raises Price Target from \$3 to \$6, Maintains Outperform

Financial news for ZGNX dated on 2013-10-28: Benzinga's Top #PreMarket Gainers

Financial news for ZGNX dated on 2013-10-28: Zogenix Shares Rise 17% Pre-Market; May be Attributed to \$6 PT from William Blair

Financial news for ZGNX dated on 2013-10-25: Zogenix Wins FDA Approval for Zohydro ER Capsules

Financial news for ZGNX dated on 2013-10-25: Zogenix Shares Resume, Now at \$3.20

Financial news for ZGNX dated on 2013-10-25: Shares of Zogenix to Resume Trade at 1:13PM EDT

Financial news for ZGNX dated on 2013-10-25: Zogenix Trading Halted

Financial news for ZGNX dated on 2013-10-25: FDA Approves Extended Release, Single-Entity Hydrocodone Product

Financial news for ZGNX dated on 2013-10-25: Zogenix Spikes Higher

Financial news for ZGNX dated on 2013-10-02: Morning Market Movers

Financial news for ZGNX dated on 2013-09-10: UPDATE: FDA Will Be Holding an Official Briefing at 12:45PM EDT to Discuss an Undisclosed Topic

Financial news for ZGNX dated on 2013-09-10: FDA Traders Considering Admin. Updates Labels on Long-Acting Painkillers

Financial news for ZGNX dated on 2013-09-10: Zogenix Shares Moving Higher; May be Attributed to 12:45PM ET FDA Announcement

Financial news for ZGNX dated on 2013-08-08: Zogenix, Inc. Reports Q2 EPS of \$(0.13) vs \$(0.15) Est

Financial news for ZGNX dated on 2013-06-27: UPDATE: Zogenix and Valeant Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Migranal Nasal Spray

Financial news for ZGNX dated on 2013-06-27: Zogenix and Valeant in Pact for Migranal Nasal Spray

Financial news for ZGNX dated on 2013-06-25: Zogenix Unveils Improved Migraine Toolbox

Financial news for ZGNX dated on 2013-06-24: ViroPharma and Other Biotech Stocks Recommended by Oppenheimer (VPHM)

Financial news for ZGNX dated on 2013-06-21: UPDATE: Oppenheimer Assumes Zogenix at Perform on Fair Valuation

Financial news for ZGNX dated on 2013-06-20: Oppenheimer Reinstates Perform on Zogenix, Inc.

Financial news for ZGNX dated on 2013-06-05: Afternoon Market Losers

Financial news for ZGNX dated on 2013-06-05: Zogenix Announces Plans to Hit Business Milestones, Confirms Cutting of 55 Employees

Financial news for ZGNX dated on 2013-06-04: Form 8-K from Zogenix Showing Co. Cutting Headcount by 55 Employees, Expecting \$1M Charge

Financial news for ZGNX dated on 2013-05-20: Zogenix-Battelle to Issue New Positive Data for Dosepro

Financial news for ZGNX dated on 2013-05-09: Zogenix, Inc. Reports Q1 EPS of \$(0.17) vs \$(0.14) Est; Revenue of \$6.98M vs \$9.28M Est

Financial news for ZGNX dated on 2013-04-17: Zogenix Shares Plunge as FDA Bans Generic Versions of Purdue's Older OxyContin; Wells Fargo Says Zogenix May Benefit from News

Financial news for ZGNX dated on 2013-04-05: Zogenix Spikes Lower

Financial news for ZGNX dated on 2013-03-15: Zogenix, Inc. Reports Q4 EPS of \$(0.16) vs \$(0.17) Est; Revenue of \$9.50M vs \$9.87M Est

Financial news for ZGNX dated on 2013-03-15: US Stock Futures Slightly Lower Ahead Of CPI

Financial news for ZGNX dated on 2013-03-15: Earnings Scheduled For March 15, 2013

Financial news for ZGNX dated on 2013-03-05: UPDATE: Brinson Patrick Initiates Zogenix at Market Putperform on Zohydro Prospects

Financial news for ZGNX dated on 2013-03-05: Brinson Patrick Initiates Coverage on Zogenix, Inc. at Market Outperform, Announces \$5.00 PT

Financial news for ZGNX dated on 2013-02-27: Benzinga's Small Cap Movers for Wednesday February 27, 2013

Financial news for ZGNX dated on 2013-02-26: Zogenix Unlikely to Receive Action Letter for NDA for Zohydro ER by PDUFA Goal Date of March 1, 2013

Financial news for ZGNX dated on 2013-01-07: Zogenix Files \$75M Mixed Securities Shelf

Financial news for ZGNX dated on 2013-01-07: Zogenix Sees Q4 Sales of \$13.4M, Unit Volume Up 9% QoQ; Cited Effect from Hurricane Sandy

Financial news for ZGNX dated on 2013-01-03: Zogenix Announces Positive Relday Phase 1 Clinical Trial Results

Financial news for ZGNX dated on 2012-12-18: Zogenix Shares Rally as FDA Reschedules Hydrocodone Drugs Panel

Financial news for ZGNX dated on 2012-12-10: UPDATE: Stifel Nicolaus Downgrades Zogenix to Hold Following FDA Panel

Financial news for ZGNX dated on 2012-12-10: UPDATE: Oppenheimer Downgrades Zogenix to Perform Following Negative Panel

Financial news for ZGNX dated on 2012-12-10: Morning Market Losers

Financial news for ZGNX dated on 2012-12-10: Stifel Nicolaus Downgrades Zogenix, Inc. to Hold, Removes \$6.00 PT

Financial news for ZGNX dated on 2012-12-10: Zogenix Shares Fall 43% Pre-Market Following Failure to Get FDA Panel OK on Zohydro

Financial news for ZGNX dated on 2012-12-10: Oppenheimer Downgrades Zogenix, Inc. to Perform, Removes \$3.00 PT

Financial news for ZGNX dated on 2012-12-07: Zogenix's Zohydro Fails to Win FDA Panel Backing

Financial news for ZGNX dated on 2012-12-07: FDA Panel Says Zogenix's Zohydro Unsafe for Intended Patients

Financial news for ZGNX dated on 2012-12-07: FDA Panel Says Zogenix's Zohydro Effective for Chronic Pain

Financial news for ZGNX dated on 2012-12-07: Zogenix to Host Conference Call Following FDA Panel Meeting, Will Be at 6:30PM

Financial news for ZGNX dated on 2012-12-07: Zogenix Halted Ahead of FDA Panel

Financial news for ZGNX dated on 2012-11-26: Zogenix Announces New Chief Commercial Officer

Financial news for ZGNX dated on 2012-11-26: Zogenix Names R. Scott Shively as New Chief Commercial Officer

Financial news for ZGNX dated on 2012-11-08: Zogenix Says FDA Panel Will Review Zohydro on Dec. 7th

Financial news for ZGNX dated on 2012-10-04: Stocks Hitting 52-Week Highs

Financial news for ZGNX dated on 2012-08-09: UPDATE: Stifel Nicolaus Reduces PT to \$6 on Zogenix on Dilutive Deal

Financial news for ZGNX dated on 2012-08-09: Stifel Nicolaus Maintains Zogenix at Buy, Lowers PT from \$7 to \$6

Financial news for ZGNX dated on 2012-08-09: Oppenheimer Maintains Zogenix at Outperform, Lowers PT from \$4 to \$3

Financial news for ZGNX dated on 2012-08-08: Zogenix Reports Q2 EPS \$-0.26 vs \$-0.28 Est; Revenues \$\$8.03 vs \$8.79M Est

Financial news for ZGNX dated on 2012-07-23: Zogenix Announces Proposed Public Offering of Common Stock and Warrants to Purchase Common Stock

Financial news for ZGNX dated on 2012-07-16: Zogenix Pops on FDA Acceptance for Review of Zohydro ER NDA

Financial news for ZGNX dated on 2012-07-14: Benzinga's Microcap Movers for Friday July 13, 2012

Financial news for ZGNX dated on 2012-07-12: Zogenix Begins Relday(TM) Clinical Trial for Schizophrenia

Financial news for ZGNX dated on 2012-06-07: Zogenix and Mallinckrodt, a Covidien Company, Enter Exclusive Co-Promotion Agreement for SUMAVEL DosePro

Financial news for ZGNX dated on 2012-05-30: Benzinga's Microcap Movers for Wednesday May 30, 2012

Financial news for ZGNX dated on 2012-05-30: Zogenix Submits IND for Second DosePro(R) Candidate Relday(TM)

Financial news for ZGNX dated on 2012-05-14: Zogenix Reports Q1 EPS \$-0.16 vs \$-0.14 Est; Revenues \$18.4M vs \$17.14M Est

Financial news for ZGNX dated on 2012-03-29: Zogenix and Battelle Ink Marketing Agreement for DosePro Drug Delivery Technology

Financial news for ZGNX dated on 2012-03-29: Zogenix and Battelle Ink Marketing Agreement for DosePro Drug Delivery Technology

Financial news for ZGNX dated on 2012-03-09: UPDATE: Stifel Nicolaus Cuts PT to \$7 on Zogenix

Financial news for ZGNX dated on 2012-03-09: Stifel Nicolaus Maintains Zogenix at Buy, Lowers PT from \$8 to \$7

Financial news for ZGNX dated on 2012-03-08: Zogenix Reports Q4 EPS \$-0.36 vs \$-0.34 Est; Revenues \$7.9M vs \$10.03M Est

Financial news for ZGNX dated on 2012-02-03: Zogenix Files for \$75M Mixed Security Shelf

Financial news for ZGNX dated on 2012-01-26: Zogenix Trading 12.7% Higher on Heavy Volume; Currently at \$2.75

Financial news for ZGNX dated on 2012-01-25: Zogenix and Battelle to Collaborate on Advanced Drug Delivery Technology

Financial news for ZGNX dated on 2011-12-28: Microcap Movers for Wednesday December 28, 2011

Financial news for ZGNX dated on 2011-12-28: Earlier Rise in Zogenix Due to Reports of Stonger Vicodin Substitute

Financial news for ZGNX dated on 2011-12-21: UPDATE: Zogenix Reviews Positive Sales Trends and 2012 Commercial Initiatives for SUMAVEL DosePro

Financial news for ZGNX dated on 2011-12-21: Zogenix and Astellas Agree to End Co-Promotion for SUMAVEL DosePro Effective March 31, 2012

Financial news for ZGNX dated on 2011-12-20: Zogenix Completes Zohydro Pre-NDA Meetings With FDA

Financial news for ZGNX dated on 2011-11-11: UPDATE: Oppenheimer Lowers PT to \$4 on Zogenix

Financial news for ZGNX dated on 2011-11-11: Oppenheimer Lowers PT on Zogenix to \$4

Financial news for ZGNX dated on 2011-09-30: Zogenix Achieves Zohydro Long-Term Safety Database for NDA

Financial news for ZGNX dated on 2011-09-26: UPDATE: Zogenix Lowers Price Target on Zogenix to \$5

Financial news for ZGNX dated on 2011-09-26: Oppenheimer Lowers PT on Zogenix to \$5

Financial news for ZGNX dated on 2011-09-20: Zogenix Spiking Higher on Heavy Volume

Financial news for ZGNX dated on 2011-09-16: Zogenix Prices 30M Share Public Offering at \$2.00/Share

Financial news for ZGNX dated on 2011-08-24: Zogenix Files Statement for Follow-On Offering of 12M Shares

Financial news for ZGNX dated on 2011-08-24: Zogenix Files Registration Statement for Proposed Follow-On Offering

Financial news for ZGNX dated on 2011-08-17: Zogenix Reports Positive Phase 3 Results for Zohydro -- Meets Primary Efficacy Endpoint

Financial news for ZGNX dated on 2011-08-16: Zogenix to Hold Conference Call to Discuss Pivotal Phase 3 Results for Zohydro for Treatment of Chronic Pain

Financial news for ZGNX dated on 2011-08-10: Zogenix Reports Q2 EPS \$(0.56) vs \$(0.52) Est

Financial news for ZGNX dated on 2011-08-10: Zogenix Reports Q2 EPS \$(0.56) vs \$(0.52) Est; Revenues \$10.2M vs \$11.13M Est

Financial news for ZGNX dated on 2011-07-18: Zogenix Closes \$30 Million Royalty Financing With Cowen Healthcare Royalty Partners II

Financial news for ZGNX dated on 2011-07-12: Zogenix to Develop and Commercialize Proprietary Long-Acting Risperidone Formulation for Needle-Free Subcutaneous Administration Using the DosePro Delivery System and DURECT's SABER Depot Technology